Please login to the form below

Not currently logged in
Email:
Password:

Adaptimmune appoints former GSK executives

Dr Rafael Amado and Adrian Rawcliffe join the biotech’s top ranks

Rafael AmadoAdaptimmune has strengthened its senior management team with the appointment of Dr Rafael Amado, as its new chief medical officer, and Adrian Rawcliffe, as its chief financial officer.

The appointments are effective from 16 March and will see Dr Amado lead Adaptimmune's clinical strategy and assume responsibility for the company's clinical trials across the US and Europe under its strategic collaboration with GlaxoSmithKline.

He will also lead the development of the company's pipeline of research programmes.

Adrian RawcliffePrior to joining Adaptimmune, Dr Amado served as senior VP and head of oncology R&D at GSK, where he was responsible for integrating oncology global R&D activities, from drug target identification to clinical development and registration.

Dr Amado said: “I am pleased to be joining Adaptimmune at this exciting time. I have been impressed by the quality of the science and look forward to working with the team as we seek to bring potential breakthrough cancer therapies to patients.”

Meanwhile Rawcliffe will lead Adaptimmune's financial management and operations functions including compliance and risk management.

He also joins from GSK where he was senior VP of finance at its North American pharmaceuticals business.

James Noble, chief executive Officer of Adaptimmune, said: “I am delighted that Rafael and Ad are joining the company. Each brings a wealth of invaluable experience to complement the expertise of our existing senior management team.”

5th March 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics